Progress in SPECT/CT imaging of prostate cancer

Technology in Cancer Research and Treatment

Volumn 5, Issue 4, 2006, Pages 329-336

  Seo, Youngho ^a   Franc, Benjamin L ^a,b,c   Hawkins, Randall A ^a,b,c   Wong, Kenneth H ^b,c,e   Hasegawa, Bruce H ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Etcheverry Hall MCI 730   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

And Collimator model; Attenuation correction; Capromab pendetide; Combined SPECT CT imaging; Indium 111; Iterative reconstruction; Prostate cancer

Indexed keywords

CAPROMAB PENDETIDE IN 111;

ALGORITHM; ARTICLE; ARTIFACT; BLOOD VESSEL; BONE MARROW; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DEVICE; DIAGNOSTIC IMAGING; DRUG UPTAKE; HUMAN; IMAGE PROCESSING; IMAGE RECONSTRUCTION; IMAGING SYSTEM; INTESTINE; MALE; METASTASIS; PROGNOSIS; PROSTATE; PROSTATE CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION; TREATMENT PLANNING;

EID: 33748036069     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460600500404     Document Type: Article

References (19)

1. Jemal, A., Murray, T., Ward, E., et al. Cancer Statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005).
2. Yoon, J. H., Chen, M. H., Renshaw, A. A., Richte, J. P., D'Amico, A. V. Predictive Factor Analysis as the Basis for the Clinical Utility of Percent Positive Prostate Biopsies in Patients with Intermediate-risk Prostate Cancer. Urology. 60, 454-457 (2002).
3. Partin, A. W., Mangold, L. A., Lamm, D., et al. Contemporary Update of Prostate Cancer Staging Nomograms (Partin Tables) for the New Millennium. Urology. 58, 843-848 (2001).
4. Seaward, S. A., Weinberg, V., Lewis, P., et al. Improved Freedom from PSA Failure with Whole Pelvic Irradiation for High-risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics 42, 1055-1062 (1998).
5. Chang, S. S., Heston, W. D. W. The Clinical Role of Prostate-specific Membrane Antigen (PSMA). Urol. Oncol. 7, 7-12 (2002).
6. Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D., Cordon-Cardo, C. Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues. Clin. Cancer Res. 3, 81-85 (1997).
7. Bander, N. H., Nanus, D. M., Milowsky, M. I., et al. Targeted Systemic Therapy of Prostate Cancer with a Monoclonal Antibody to Prostate-specific Membrane Antigen. Semin Oncol. 30, 667-676 (2003).
8. Haseman, M. K., Rosenthal, S. A., Polascik, T. J. Capromab Pendetide Imaging of Prostate Cancer. Cancer Biother. Radiopharm. 15, 131-140 (2000).
9. Da Silva, A. J., Tang, H. R., Wu, M. C., Hasegawa, B. H. Absolute Quantitation of Myocardial Activity in Phantoms. IEEE Trans. Nucl. Sci. 46, 659-666 (1999).
10. Seo, Y., Wong, K. H., Sun, M., et al. Correction of Photon Attenuation and Collimator Response for a Body-contouring SPECT/CT Imaging System. J. Nucl. Med. 46, 868-877 (2005).
11. Tang, H. R., Brown, J. K., Hasegawa, B. H. An X-ray CT-assisted Method for Radionuclide Activity Measurement Using Planar Views. IEEE Nuclear Science Symposium/Medical Imaging Conference. Albuquerque, NM, USA. 1997.
12. Wilk, M., Yuzefovich, I., Carmi, R., Shrem, Y. Practical Multi-peak Attenuation Correction with CT Data. J. Nucl. Med. 43, 221 (2002).
13. Seo, Y., Wong, K. H., Hasegawa, B. H. Calculation and Validation of the Use of Effective Attenuation Correction for Attenuation Correction in In-111 SPECT. Med. Phys. 32, 3628-3635 (2005).
14. 111Indium- capromab pendetide in the Evaluation of Patients with Residual or Recurrent Prostate Cancer After Radical Prostatectomy. J. Urol. 159, 2041-2046 (1998).
15. Bander, N. H. Technology Insight: Monoclonal Antibody Imaging of Prostate Cancer. Nat. Clin. Pract. Urol. 3, 216-225 (2006).
16. Schettino, C. J., Kramer, E. L., Noz, M. E., et al. Impact of Fusion of Indium-111 Capromab Pendetide Volume Data Sets with Those from MRI or CT in Patients with Recurrent Prostate Cancer, AJR Am. J. Roentgenol. 183, 519-524 (2004).
17. Haseman, M. K., Rosenthal, S. A., Polascik, T. J. Capromab Pendetide Imaging of Prostate Cancer. Cancer Biother. Radiopharm. 15, 131-140 (2000).
18. Wong, T. Z., Turkington, T. G., Polascik, T. J., Coleman, R. E., ProstaScint (Capromab Pendetide) Imaging Using Hybride Gamma Camera-CT Technology. AJR Am. J. Roentgenol. 184, 676-680 (2005).
19. 177lutetium-labeled J591, A Monoclonal Antibody to Prostate-specific Membrane Antigen, in Patients with Androgen-independent Prostate Cancer. J. Clin. Oncol. 23, 4591-4601 (2005).